Tepotinib
|
|
Tepotinib 속성
- 끓는 점
- 626.5±65.0 °C(Predicted)
- 밀도
- 1.25
- 저장 조건
- Store at -20°C
- 물리적 상태
- Solid
- 산도 계수 (pKa)
- 8.93±0.10(Predicted)
- 수용성
- ≥ 4.93 mg/mL in DMSO, <2.52 mg/mL in EtOH, <2.56 mg/mL in Water
- InChIKey
- AHYMHWXQRWRBKT-UHFFFAOYSA-N
- SMILES
- C(#N)C1=CC=CC(C2=NN(CC3=CC=CC(C4=NC=C(OCC5CCN(C)CC5)C=N4)=C3)C(=O)C=C2)=C1
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
| 그림문자(GHS): |
|
||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 신호 어: | Warning | ||||||||||||||
| 유해·위험 문구: |
|
||||||||||||||
| 예방조치문구: |
|
Tepotinib C화학적 특성, 용도, 생산
개요
Tepotinib is a highly selective inhibitor against MET. In xenograft models, acquired resistance to EGFR TKIs via secondary EGFR T790 M mutations can be overcome with tepotinib treatment.용도
EMD 1214063 is a novel ATP-comptetitive inhibitor of the MET hepatocyte growth factor receptor and a novel kinase inhibitor and a therapeutic agent for neuroblastoma. Potent c-MET inhibitor.상표명
TepmetkoMechanism of action
Tepotinib is a Kinase Inhibitor. The mechanism of action of tepotinib is as a Mesenchymal Epithelial Transition Inhibitor, and P-Glycoprotein Inhibitor.Clinical Use
Tepotinib is currently being evaluated in combination with EGFR TKI gefitinib and also a separate trial in NSCLC patients with MET exon 14 skipping mutation and MET amplification.Drug interactions
Tepotinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have mesenchymal-epithelial transition (_MET_) exon 14 skipping alterations.신진 대사
Tepotinib is metabolized primarily by CYP3A4 and CYP2C8, with some apparent contribution by unspecified UGT enzymes. The metabolite M506 is the major circulating metabolite, comprising approximately 40.4% of observed drug material in plasma, while the M668 glucuronide metabolite has been observed in plasma at much lower quantities (~4% of an orally administered dose). A total of 10 phase I and phase II metabolites have been detected following tepotinib administration, most of which are excreted in the feces.Tepotinib 준비 용품 및 원자재
원자재
tert-butyl 4-(((2-(3-((3-(3-cyanophenyl)-6-oxopyridazin-1(6H)-yl)methyl)phenyl)pyrimidin-5-yl)oxy)methyl)piperidine-1-carboxylate
BenzeneMethanol, 3-[5-[(1-Methyl-4-piperidinyl)Methoxy]-2-pyriMidinyl]-
3-(6-Oxo-1,6-dihydro-3-pyridazinyl)benzonitrile, 97%
준비 용품
Tepotinib 공급 업체
글로벌( 164)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| ATK CHEMICAL COMPANY LIMITED | +undefined-21-51877795 |
ivan@atkchemical.com | China | 32760 | 60 |
| Hubei Jusheng Technology Co.,Ltd. | 18871490254 |
linda@hubeijusheng.com | CHINA | 28180 | 58 |
| BOC Sciences | +1-631-485-4226 |
inquiry@bocsci.com | United States | 19553 | 58 |
| career henan chemical co | +86-0371-86658258 +8613203830695 |
factory@coreychem.com | China | 29826 | 58 |
| HANGZHOU CLAP TECHNOLOGY CO.,LTD | 86-571-88216897,88216896 13588875226 |
sales@hzclap.com | CHINA | 6313 | 58 |
| Dideu Industries Group Limited | +86-29-89586680 +86-15129568250 |
1026@dideu.com | China | 26267 | 58 |
| Shenzhen Shengda Pharma Limited | 755-85269922 +8613424394241 |
sales@shengdapharm.com | CHINA | 310 | 58 |
| Zhejiang J&C Biological Technology Co.,Limited | +1-2135480471 +1-2135480471 |
sales@sarms4muscle.com | China | 10522 | 58 |
| InvivoChem | +1-708-310-1919 +1-13798911105 |
sales@invivochem.cn | United States | 6393 | 58 |
| Shanghai Innopharm Industrial Co., Ltd. | +86-21-59960785 +86-17701845089 |
sales@hoyaopharm.com | China | 314 | 58 |